Publish Date : 03-Aug-2012
Masimo, the inventor of rainbow® Pulse CO-Oximetry™, and SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced it has acquired PHASEIN AB (Stockholm, Sweden), a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions.
The acquisition of PHASEIN\'s multigas technologies complements Masimo\'s breakthrough innovations for patient monitoring with a portfolio of products ranging from OEM solutions for external \"plug-in-and-measure\" gas analyzers and integrated modules to handheld devices. With multiple measurements delivered through either mainstream or sidestream options, Masimo customers can now benefit from CO2, N2O, O2, and anesthetic agent monitoring in many hospital environments, such as operating rooms, procedural sedations and intensive care units.
Joe Kiani, Masimo CEO and Chairman of the Board, stated, \"We are confident that the best technology always wins if clinicians are given the choice. PHASEIN has developed leading-edge infrared multispectral technologies for measuring respiratory gases. In our assessment, PHASEIN has the most accurate gas measurements, the widest array of measurements, and the technology most suited for easy and flexible integration in both Masimo and OEM products. PHASEIN\'s impressive list of OEM customers and innovative technology portfolio for monitoring CO2, N2O, O2, and anesthetic agents is a perfect addition to Masimo\'s mission to take noninvasive patient monitoring to new sites and applications. We see multigas measurements as a half-billion dollar global market opportunity and are proud to welcome the PHASEIN team to the Masimo team.\"
PHASEIN CEO Robert Zyzanski will remain the CEO of the company. \"Masimo\'s pursuit of innovation for the betterment of patient care is bar none. The opportunity to become part of Masimo is yet another validation of our advanced capnography and gas monitoring technologies,\" Zyzanski said. \"We look forward to continuing to develop industry-leading solutions with our new colleagues, as we strive to leverage the synergies of our complementary technologies to improve patient outcomes and reduce the cost of care worldwide.\"
Masimo paid approximately $30.4 million in cash to purchase PHASEIN. No other terms were disclosed. The estimated impact of the acquisition on Masimo\'s 2012 financial results will be included in the company\'s second quarter earnings announcement, set for release after the market close today.
Go to previous page
